Traumatic Brain Injury Outcomes After Recreational Cannabis Use
Jerzy P Szaflarski,Magdalena Szaflarski,Jerzy Szaflarski
DOI: https://doi.org/10.2147/ndt.s453616
IF: 2.989
2024-04-04
Neuropsychiatric Disease and Treatment
Abstract:Jerzy P Szaflarski, 1 Magdalena Szaflarski 2 1 Department of Neurology, University of Alabama at Birmingham (UAB), Heersink School of Medicine, Birmingham, AL, USA; 2 Department of Sociology, University of Alabama at Birmingham (UAB), Birmingham, AL, USA Correspondence: Jerzy P Szaflarski, Department of Neurology, University of Alabama at Birmingham (UAB) Heersink School of Medicine, 312 Civitan International Research Center1719 6th Avenue South, Birmingham, AL, 35294-0021, USA, Email Purpose: Basic science data indicate potential neuroprotective effects of cannabinoids in traumatic brain injury (TBI). We aimed to evaluate the effects of pre-TBI recreational cannabis use on TBI outcomes. Patients and Methods: We used i2b2 (a scalable informatics framework; www.i2b2.org ) to identify all patients presenting with acute TBI between 1/1/2014 and 12/31/2016, then conducted a double-abstraction medical chart review to compile basic demographic, urine drug screen (UDS), Glasgow Coma Scale (GCS), and available outcomes data (mortality, modified Rankin Scale (mRS), duration of stay, disposition (home, skilled nursing facility, inpatient rehabilitation, other)) at discharge and at specific time points thereafter. We conducted multivariable nested ordinal and logistic regression analyses to estimate associations between cannabis use, other UDS results, demographic factors, and selected outcomes. Results: i2b2 identified 6396 patients who acutely presented to our emergency room with TBI. Of those, 3729 received UDS, with 22.2% of them testing positive for cannabis. Mortality was similar in patients who tested positive vs negative for cannabis (3.9% vs 4.8%; p = 0.3) despite more severe GCS on admission in the cannabis positive group (p = 0.045). Several discharge outcome measures favored the cannabis positive group who had a higher rate of discharge home vs other care settings (p < 0.001), lower discharge mRS (p < 0.001), and shorter duration of hospital stay (p < 0.001) than the UDS negative group. Multivariable analyses confirmed mostly independent associations between positive cannabis screen and these post-TBI short- and long-term outcomes. Conclusion: This study adds evidence about the potentially neuroprotective effects of recreational cannabis for short- and long-term post-TBI outcomes. These results need to be confirmed via prospective data collections. Keywords: cannabis, traumatic brain injury, Glasgow Coma Scale, GCS, outcomes, modified Rankin Scale, mRS Every year, traumatic brain injury (TBI) affects over 2 million individuals in the US with a global estimate of 69 million new cases. 1,2 Among various negative long-term sequelae, deficits in information processing, attention, working memory, and executive functioning occur in up to 65% of TBI survivors. 3 These deficits interfere with independence and reintegration into society, affect family functioning and well-being, and produce significant caregiver strain. 4,5 However, despite many past studies, there is no specific treatment to ameliorate the emergence of post-TBI deficits. 6,7 Thus, it is important to develop investigations into the factors that shape post-TBI outcomes. In response to TBI, brain undergoes many primary and secondary structural, metabolic, and vascular changes. 8–10 These changes include increases in pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α 11–14 and changes in molecular pathways for chronic inflammatory transmitters such as vascular cell adhesion molecule-1 (VCAM-1) and cannabinoid receptor-2 (CB 2 R), a marker of neuroinflammation predominantly expressed in activated microglia. 15–17 There is evidence that the neuroinflammatory cascade is involved in producing some of the deficits seen after TBI 18–23 and that blocking neuroinflammation during the acute phase of TBI may be neuroprotective. 24,25 As part of the neuro-metabolic response to TBI, the endocannabinoid system (ECS) offers a potential route for modifying neuroinflammation via its interactions with neurons and glia. 26,27 The interaction between phytocannabinoids, terpenes, and flavonoids and the ECS and other homeostatic systems has been studied in a substantial detail. 28 This includes not only anti-inflammatory and neuroprotective investigations but also research into the effects of phyto- and endocannabinoids on epileptogenesis and cognition. 29–31 Thus, basic and clinical science work has made important strides toward understanding the divergent roles of the ECS and the dynamics of its receptors (CB 1 R/CB 2 R) and neurotransmitter -Abstract Truncated-
psychiatry,clinical neurology